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ABSTRACT
Docetaxel is the standard chemotherapy for metastatic castration-resistant 
prostate cancer (CRPC). However, nearly all patients ultimately become refractory due 
to the development of docetaxel resistance. The transcribed ultraconserved regions 
(T-UCRs) are a novel class of non-coding RNAs that are absolutely conserved across 
species and are involved in carcinogenesis including prostate cancer (PC). In this 
study, we investigated the transcriptional levels of 26 representative T-UCRs and 
determined the regions that were differentially expressed in PC. Quantitative real-time 
polymerase chain reaction analysis revealed that the expression of T-UCR Uc.63+ was 
increased in PC tissues. MTT assay and wound healing assay revealed that Uc.63+ was 
involved in cell growth and cell migration. miR-130b was predicted to have binding 
sites within the Uc.63+ sequence. The expression of miR-130b was significantly 
disturbed by the overexpression or knockdown of Uc.63+. We also showed that 
Uc.63+ regulated the expression of MMP2 via miR-130b regulation. Furthermore, 
overexpression of Uc.63+ increased the expression of AR and its downstream molecule 
PSA and promoted resistance to docetaxel through AR regulation. In patients treated 
with docetaxel, the expression of serum Uc.63+ in the docetaxel-resistant patients 
was higher than that in the docetaxel-sensitive patients (P = 0.011). Moreover, 
Kaplan-Meier analysis showed that the high expression of serum Uc.63+ correlated 
with a worse prognosis (P = 0.020). These results substantially support the important 
role that Uc.63+ plays in PC progression by interacting with miR-130b and indicate 
that Uc.63+ could potentially be a promising serum marker for deciding the best 
treatment for patients with CRPC.
INTRODUCTION
Prostate cancer (PC) is the most prevalent cancer 
among men and the second leading cause of cancer-related 
death in developed countries [1]. Androgen receptor (AR) 
is largely involved in the development and growth of PC 
[2], and most patients with PC are initially sensitive to 
androgen deprivation therapy. However, most of these 
patients eventually develop castration-resistant PC 
(CRPC) (defined as disease progression during androgen-
ablation therapy despite secondary hormone therapy) that 
will inevitably result in metastasis and death [3]. Although 
docetaxel is the standard chemotherapy for CRPC [4], 
nearly all patients with docetaxel chemotherapy become 
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refractory probably due to restoration of AR signaling 
caused by AR gene amplification and mutations, which 
are critical events in patients with CRPC [5]. Therefore, 
identifying new molecular mechanisms underlying 
aberrant AR activation and docetaxel resistance hold great 
promise to improve chemotherapy for CRPC.
Recently, many reports have shown that noncoding 
RNAs (ncRNAs) are most likely to be crucial regulators 
of development and progression in PC [6]. Despite the 
pivotal role of AR in the development and progression 
in PC, there is little evidence that ncRNAs have been 
implicated in the regulation of AR signaling [7], [8]. 
Among several classes of ncRNAs, a genome-wide 
survey identified 481 ncRNAs with a size > 200 bp that 
are absolutely conserved (100%) between the orthologous 
regions among most of the vertebrate genomes [9], and 
these have been named transcribed ultraconserved regions 
(T-UCRs). Given that T-UCRs are conserved across 
species, they are believed to play critical roles in human 
development and disease. Two main mechanisms have 
been described as the regulatory machinery controlling 
the expression of T-UCRs: interactions with miRNAs and 
hypermethylation of CpG island promoters [10]. T-UCRs 
show a ubiquitous or a tissue-specific pattern and also 
exhibit distinct profiles in various human cancers [11], 
and whether T-UCRs play an oncogenic role or a tumor-
suppressive role depends on the cellular context [11], [12]. 
Based on this evidence, T-UCRs could provide useful 
markers to classify the characteristics of human cancer, 
diagnostic markers for some specific types of cancer, and 
predictive markers for drug sensitivity or prognosis of 
cancer patients. We previously showed that some T-UCRs 
are aberrantly expressed in PC and are silenced by DNA 
methylation [12]; however, further in-depth studies are 
needed to determine the complete picture of the biological 
function of T-UCRs in PC. In this study, we evaluated the 
expression of T-UCRs in PC, investigated their functional 
roles in PC progression and AR regulation, and analyzed 
the effect of Uc.63+ on docetaxel resistance.
RESULTS
Expression profiles of T-UCR in PC
To identify ideal biomarkers and therapeutic targets 
for PC, we first analyzed 26 candidate T-UCRs that were 
upregulated in PC based on a microarray analysis [13]. 
To validate the results obtained by a microarray analysis, 
we examined the expression of these 26 T-UCRs by 
quantitative real-time polymerase chain reaction (qRT-
PCR) using 12 PC tissues and 8 non-neoplastic prostate 
tissues (Supplementary Figure 1). The mean expression 
level of each T-UCR was calculated, and the ratio of tumor/
non-neoplastic prostate (T/N ratio) was determined (Figure 
1A). We identified 3 regions (Uc.3+, Uc.4+, and Uc.63+) 
that were significantly upregulated in PC tissues compared 
with non-neoplastic prostate tissues. We then analyzed the 
expression of these 3 regions in PC cell lines (LNCaP, 
DU145, and PC3) and revealed that the expression of 
Uc.63+ in PC cell lines was elevated compared with that 
in non-neoplastic tissues. In contrast, the expression of 
Uc.3+ and Uc.4+ in PC cell lines was lower than that 
in the non-neoplastic prostate tissues (Supplementary 
Figure 2). Given these results, we decided to focus on 
Uc.63+. Then, we examined the expression of Uc.63+ 
in 14 types of normal tissue samples and 20 PC tissues 
from another cohort/sample set by qRT-PCR. Among these 
normal tissue samples, the highest expression of Uc.63+ 
was found in the pancreas. However, the expression of 
Uc.63+ in PC tissues was higher than that in the pancreas 
(Figure 1B). In this sample set, the expression of Uc.63+ 
was significantly associated with high Gleason score (P = 
0.007) and high prostate-specific antigen (PSA) level (P < 
0.001) (Figure 1C). To further investigate the usefulness 
of Uc.63+ as a serum biomarker for PC, we examined 
the expression of Uc.63+ in the serum of 10 patients 
with benign prostatic hyperplasia (BPH), 24 patients 
with primary PC, and 45 patients with metastatic PC by 
droplet digital PCR (ddPCR). Representative images of 
ddPCR are shown in Supplementary Figure 3. ddPCR 
analysis determined that significantly higher expression 
of Uc.63+ was detected in metastatic PC than in BPH 
and primary PC (Figure 1D). Moreover, the expression 
of Uc.63+ was significantly elevated in the serum from 
primary PC compared with that in the serum from BPH 
(Supplementary Figure 4). The expression of Uc.63+ 
was correlated with PSA concentration in the serum from 
primary PC and metastatic PC. (Supplementary Figure 5). 
Additionally, we identified significantly higher expression 
of Uc.63+ in the serum of CRPC patients than that in 
hormone-dependent PC patients (Figure 1E). To clarify the 
localization of Uc.63+, we performed in situ hybridization 
of Uc.63+ in PC tissues and found that robust expression 
of Uc.63+ was observed in the nucleus in PC tissues, 
whereas the expression of Uc.63+ was rarely detected in 
non-neoplastic prostate tissues (Figure 1F).
Uc.63+ acts as an oncogene and is associated 
with cell proliferation and cell migration
To elucidate the biological roles of Uc.63 in PC, we 
first constructed a vector containing the whole sequence of 
Uc.63+ and transfected it into LNCaP cells that possessed 
a low level of Uc.63+. As shown in Figure 2A, transfection 
of the vector significantly induced Uc.63+ overexpression. 
Next, we performed a 4,5-dimethylthiazol-2-yl-2,5-
diphenyltetrazolium bromide (MTT) assay and wound 
healing assay. LNCaP cells transfected with the Uc.63+ 
expression vector showed significantly increased cell 
proliferation and migration (Figure 2B, 2C). To further 
verify whether Uc.63+ is required for cell proliferation 
and migration, we investigated the effects on the 
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downregulation of Uc.63+ by using small interfering RNA 
(siRNA) that was designed to specifically target Uc.63+. 
We confirmed a significantly lower expression of Uc.63+ 
in DU145 and PC3 cells with two different siRNAs than 
that in the negative control (Figure 2D). Following these 
results, we examined the MTT assay and wound healing 
assay and found that knockdown of Uc.63+ reduced cell 
proliferation and migration (Figure 2E, 2F). These results 
showed that Uc.63+ has an apparent oncogenic role in PC.
Uc.63+ and XPO1 are independently regulated
Based on data from the National Center for 
Biotechnology Information, Uc.63+ is located in 
the third intron of the XPO1 gene on chromosome 2 
(Supplementary Figure 6A). To evaluate the relationship 
between Uc.63+ and the host gene XPO1 transcription, 
we examined the expression of XPO1 by qRT-PCR in 
PC tissues. We designed the primers to cover one of 
the exons of XPO1, which does not include the Uc.63+ 
coding region. The expression of XPO1 did not correlate 
with that of Uc.63+ (Supplementary Figure 6B). As we 
expected, knockdown of the expression of Uc.63+ had 
no effect on the expression of XPO1 in DU145 and PC3 
cells, and the expression of XPO1 was not changed in 
LNCaP cells transfected with the Uc.63+ expression 
vector (Supplementary Figure 6C, 6D). These results 
suggested that the expression of Uc.63+ and XPO1 are 
independently regulated, which is consistent with a 
previous finding [14].
Figure 1: The expression of transcribed ultraconserved regions (T-UCRs) in prostate cancer (PC). (A) The fold difference 
indicates the ratios of T-UCR expression in PC tissues compared with non-neoplastic tissues. (B) qRT-PCR analysis of the expression 
of Uc.63+ in 14 kinds of normal tissues and 20 PC samples. (C) Scatter plot diagrams showing the association between the expression 
of Uc.63+ and clinicopathological findings (Gleason score [GS], prostate-specific antigen [PSA]). Statistical differences were evaluated 
with the Mann-Whitney U-test. (D) Results of droplet digital PCR (ddPCR) for the expression of Uc.63+ in serum of patients with benign 
prostatic hyperplasia (BPH), primary PC (localized PC), and meta PC (PC with metastatic sites). Statistical differences were evaluated 
with the Mann-Whitney U-test. (E) Results of ddPCR for the expression of Uc.63+ in serum in hormone-dependent PC (HDPC) and 
castration-resistant PC (CRPC). Statistical differences were evaluated with the Mann-Whitney U-test. (F) In situ hybridization analysis 
for the expression of Uc.63+ in PC and non-neoplastic prostate. Representative imagines with low (left panels) and high (right panels) 
magnifications were shown. Scale bars, 50 μm for low magnification image (left panel); 10 μm for high magnification images (right panels).
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Uc.63+ on its own enhances the expression of AR 
and its downstream gene PSA
AR plays a central role in PC carcinogenesis, and 
a number of regulators of the AR signaling pathway 
have been identified [6]. To investigate whether Uc.63+ 
is involved in this pathway, we examined the expression 
of AR in PC tissues and non-neoplastic prostate tissues 
by qRT-PCR and found that the expression of Uc.63+ 
correlated positively with that of AR (Figure 3A). Then, 
we observed the expression of Uc.63+ in LNCaP cells 
after treatment with dihydrotestosterone (DHT) or vehicle 
to verify whether androgen regulated the expression of 
Uc.63+. Treatment with both DHT and with vehicle did 
not yield any significant upregulation of the expression of 
Uc.63+ (Figure 3B), which suggested that the expression 
of Uc.63+ is regulated in an androgen-independent 
manner. To investigate a possible role of Uc.63+ in the 
AR signaling pathway, we examined the expression of 
AR in LNCaP cells that are well established as an AR-
positive PC cell line. Western blot analysis revealed 
that overexpression of Uc.63+ increased the expression 
of AR in the presence or absence of DHT (Figure 3C). 
Additionally, we investigated the ability of Uc.63+ to 
regulate the AR downstream gene PSA. The expression of 
PSA was clearly induced in LNCaP cells treated with DHT 
compared to that in LNCaP cells treated with vehicle. 
Overexpression of Uc.63+ also increased the expression 
Figure 2: Uc.63+ promotes cell proliferation and migration in prostate cancer (PC) cells. (A) The result of qRT-PCR for the 
expression of Uc.63+ in LNCaP cells transfected with Uc.63+ expression vector or empty vector. The results are expressed as the mean ± 
S.D. of triplicate measurements. ***P <0.001. (B) Cell proliferation assay in LNCaP cells transfected with the Uc.63+ expression vector 
or empty vector. Cell growth was assessed by MTT assays at 1, 2, and 4 days after seeding on 96-well plates. Bars and error bars are the 
mean and S.D., respectively, of 3 independent experiments. *P <0.05. (C) Representative images of a wound healing assay in LNCaP 
cells transfected with the Uc.63+ expression vector or empty vector. Wound closures were evaluated by wound contraction percentage 
and closure time at 0, 12, and 24 hours after scratching. The results are expressed as the mean and S.D. of triplicate measurements. **P 
<0.01. (D) The results of qRT-PCR for the expression of Uc.63+ in PC3 cells transfected with negative control or two different siRNAs. 
The results are expressed as the mean and S.D. of triplicate measurements. **P <0.01. (E) Cell proliferation assay in PC3 cells transfected 
with negative control or two different siRNAs. Cell growth was assessed by MTT assays at 1, 2, and 4 days after seeding on 96-well plates. 
Bars and error bars are the mean and S.D., respectively, of 3 independent experiments. *P <0.05, **P <0.01. (F) Representative images of 
wound healing assays in PC3 cells transfected with negative control or two different siRNAs. Wound closures were evaluated by wound 
contraction percentage and closure time at 0, 6, and 12 hours after scratching. The results are expressed as the mean and S.D. of triplicate 
measurements. **P <0.01.
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of PSA in the presence or absence of DHT (Figure 3D). 
Similar results were obtained at the secreted protein PSA 
level (Figure 3E). Knockdown of Uc.63+ did not affect 
the expression of AR and PSA in DU145 cells, which were 
shown to be AR-negative cells by western blot analysis 
(Supplementary Figure 7A, 7B).
Uc.63+ promotes docetaxel resistance in CRPC 
patients
Several studies showed that there could be an 
interaction between AR signaling activity and docetaxel 
sensitivity [15]. Therefore, we examined the involvement 
of Uc.63+ in docetaxel resistance. We performed MTT 
assays to measure cell viability in LNCaP cells transfected 
with Uc.63+ expression vector and empty vector under 
various concentrations of docetaxel for 48 hours in the 
absence of DHT. The IC
50
 value of LNCaP cells transfected 
with Uc.63+ expression vector was significantly higher 
than that of LNCaP cells transfected with empty vector 
(Figure 4A). To further address whether the observed effect 
of Uc.63+ on docetaxel resistance is specifically caused by 
AR upregulation, we used DU145 cells, which are well 
known as an AR-negative cell line. As shown in Figure 
4B, knockdown of Uc.63+ had no effect on docetaxel 
sensitivity in the DU145 cells. To rule out the possibility 
that miR-130b was involved in docetaxel resistance, we 
examined the effect of miR-130b on docetaxel resistance. 
Overexpression of miR-130b did not affect docetaxel 
sensitivity in LNCaP cells transfected with Uc.63+ 
(LNCaP Uc.63+#1) (Supplementary Figure 8). Hence, we 
concluded that the effect of Uc.63+ on docetaxel resistance 
is mediated mainly by regulation of AR. We then elucidated 
the utility of Uc.63+ as a serum marker for predicting 
therapeutic outcomes of PC patients. We performed ddPCR 
in 27 patients with metastatic CRPC who were treated 
with docetaxel chemotherapy. We selected a cut-off point 
at the median serum level of Uc.63+ in the ddPCR data. 
The patients with high expression of UC.63+ had a lower 
PSA response rate than the patients with low expression of 
Uc.63+ (P = 0.078) (Supplementary Figure 9). Although 
these differences did not quite reach statistical significance, 
Figure 3: Uc.63+ modulates androgen receptor (AR) and its downstream gene PSA. (A) The correlation between the 
expression of Uc.63+ and the expression of AR in prostate cancer (PC) tissues. Spearman correlation coefficient and P-values are indicated. 
(B) qRT-PCR analysis for the expression of Uc.63+ in LNCaP cells in the presence of dihydrotestosterone (DHT) (10 nM) or vehicle 
(ethanol). (C) Western blot analysis of AR in LNCaP cells transfected with Uc.63+ expression vector or empty vector in the presence of 
DHT (10 nM) or vehicle (ethanol). β-actin was used as a loading control. (D, E) mRNA expression of PSA and secreted protein expression 
of PSA in LNCaP cells transfected with Uc.63+ expression vector or empty vector in the presence of DHT (10 nM) or vehicle (ethanol). 
The results are expressed as the mean and S.D. of triplicate measurements. **P <0.01, ***P <0.001.
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Uc.63+ serum levels were significantly higher in the 
docetaxel-resistant patients than in the docetaxel-sensitive 
patients (P = 0.011) (Figure 4C). Moreover, Kaplan-
Meier analysis showed the expression of Uc.63+ to be 
significantly associated with poor therapeutic outcomes in 
patients with metastatic CRPC (Log rank test, P = 0.02; 
hazard ratio 4.2) (Figure 4D).
Interaction between Uc.63+ and miR-130b
Recent evidence suggests that T-UCRs act as 
endogenous competing RNAs, and miRNA is one of the 
key regulators of T-UCRs [16]. To identify the miRNAs 
that could potentially interact with Uc.63+, we used two 
online software programs: UCbase 2.0 and miRanda. We 
detected that miR-130b and miR-605 had complementary 
sequences of Uc.63+ (Figure 5A). Further validation study 
using qRT-PCR disclosed that the expression of miR-
130b was robust both in PC tissues and in non-neoplastic 
prostate tissues, whereas miR-605 was not detectable in 
either of them (data not shown). Therefore, we focused on 
miR-130b. A higher expression of miR-130b in LNCaP 
cells was detected in comparison with that in DU145 or 
PC3 cells (Figure 5B). Furthermore, we investigated the 
expression of miR-130b in PC tissues and non-neoplastic 
prostate tissues by qRT-PCR and found that the expression 
of miR-130b inversely and significantly correlated with 
the expression of Uc.63+ (P = 0.002) (Figure 5C). There 
was significant downregulation of miR-130b in PC tissues 
compared with non-neoplastic prostate tissues (P = 
0.002) (Figure 5D). To further investigate the interaction 
between Uc.63+ and miR-130b, we examined the effect 
of Uc.63+ deregulation on the expression of miR-130b. 
Overexpression of Uc.63+ in LNCaP cells downregulated 
miR-130b (Figure 5E). Meanwhile, silencing of Uc.63+ 
in PC3 cells upregulated the expression of miR-130b 
(Supplementary Figure 10A). It has been shown that 
matrix metallopeptidase 2 (MMP2) is a direct target of 
miR-130b [17]. Western blot analysis revealed that MMP2 
was higher in LNCaP cells transfected with Uc.63+ 
expression vector than that in LNCaP cells transfected 
with empty vector (Figure 5F). As we expected, silencing 
of Uc.63+ in PC3 cells downregulated the expression 
of MMP2 by western blot analysis (Supplementary 
Figure 4: Effect of Uc.63+ on docetaxel sensitivity in prostate cancer (PC) cell lines and on clinical outcome. (A) Dose-
dependent effect of docetaxel on the viability of LNCaP cells transfected with Uc.63+ expression vector or empty vector. (B) Dose-dependent 
effect of docetaxel on the viability of DU145 transfected with negative control or two different siRNAs. (C) Box-plot representing the 
expression of Uc.63+ in chemo-sensitive and chemo-resistant patients with castration-resistant prostate cancer (CRPC). (D) Kaplan-Meier 
curves for overall survival of patients with CRPC and docetaxel chemotherapy.
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Figure 10B). To further verify that Uc.63+ was involved 
in the oncogenic role through miR-130b, we examined the 
overexpression of miR-130b in LNCaP Uc.63+#1 cells. 
qRT-PCR showed the expression of miR-130b was higher 
in LNCaP Uc.63+#1 cells transfected with miR-130b 
mimics than that in LNCaP Uc.63+#1 cells transfected 
with negative control (Figure 5G). Overexpression of 
miR-130b in LNCaP Uc.63+#1 cells downregulated the 
expression of MMP2 and migratory ability (Figure 5H, 
5I). These results suggest that Uc.63+ may upregulate 
the expression of MMP2 through miR-130b interaction, 
which is most likely to contribute to the oncogenic role 
of Uc.63+.
DISCUSSION
As we have already mentioned, T-UCRs are 
absolutely conserved among most of the vertebrate 
genomes, which means that T-UCRs could potentially 
play essential roles in ubiquitous vital phenomenon in 
comparison with the other classes of non-coding RNAs. 
Prior studies have emphasized that there are distinct 
signatures related to the expression of T-UCRs in human 
cancers, and some of the T-UCRs supposedly have 
functional roles in cancer biology, which implied that 
T-UCRs could provide valuable molecular markers and/
or therapeutic targets. In the work presented here, we 
identified the signature of T-UCRs that were differentially 
expressed in PC and extensively studied T-UCR Uc.63+ 
as it was significantly upregulated in both PC tissues and 
cell lines. One recent study reported a T-UCR signature 
that was overexpressed in PC tissue through a microarray 
analysis using 57 PC and 7 non-neoplastic prostate tissues; 
however, Uc.63+ was not chosen as a hopeful candidate. 
The actual strategy we applied in this study was to 
validate the expression of 26 T-UCRs with qRT-PCR by 
referring to the signatures reported by Hudson et al [13], 
which enabled us to focus on Uc.63+, and its functional 
roles in PC were quite consistent with those determined 
in a previous study on breast cancer [14]. One of the 
plausible explanations for the oncogenic role of Uc.63+ is 
thought to be an interaction with miR-130b that regulates 
MMP2. Several lines of study have provided evidence 
for an important role of the interaction between T-UCRs 
and miRNA in cancer biology. In this present study, we 
focused only on the interaction between Uc.63+ and miR-
130b, which would surely explain how Uc.63+ is involved 
in the regulation of PC cell migration and invasion but 
is not accountable enough for the interaction among 
Uc.63+ and PC cell growth. There could probably be a 
bunch of unknown miRNAs that are potentially regulated 
by Uc.63+, which may help to explain how Uc.63+ 
contributes to PC cell growth activity. These findings call 
for more studies on the interaction between T-UCRs and 
miRNAs to elucidate a fuller picture of the molecular 
mechanism in cancer biology.
We found that the expression of Uc.63+ correlated 
significantly with that of AR in vivo and that Uc.63+ 
could directly regulate the expression of AR in an 
androgen-independent manner in vitro, which led to 
docetaxel resistance in PC cells. To our knowledge, this 
is the first study to report the direct effect of T-UCRs 
on AR signaling and its downstream target PSA and 
the involvement of T-UCRs in the drug resistance of 
cancer cells. Several lines of evidence have shown that 
AR signaling modulates docetaxel sensitivity [15], [18], 
[19], and the recent CHAARTED clinical trial showed 
that patients with hormone-sensitive metastatic PC who 
received docetaxel chemotherapy given at the time of 
androgen deprivation therapy lived more than one year 
longer than patients who received androgen deprivation 
therapy alone [20]. We showed that overexpression of 
Uc.63+ enhanced docetaxel resistance in androgen-
dependent LNCaP cells, and knockdown of Uc.63+ 
had no effect on the docetaxel resistance in androgen-
independent DU145 cells. These results further support 
the notion that Uc.63+ is surely involved in modulation 
of the docetaxel sensitivity of PC cells through regulation 
of AR signaling. Docetaxel is the only well-established 
chemotherapeutic drug that provides a significant 
benefit to clinical outcome in CRPC patients [4]. To 
fully determine the machinery that controls docetaxel 
resistance in PC cells, further in-depth studies on which 
molecule in AR signaling is actually regulated by 
UC.63+ need to be elucidated; this could be a potential 
game changer in the treatment of PC.
One of the most important findings of this study 
was that we successfully detected the expression 
of Uc.63+ in serum samples from PC patients 
using ddPCR, which is believed to be a much more 
sophisticated method than conventional qRT-PCR. 
Although several studies have reported the expression 
of some T-UCRs in cancer tissues and cancer cell 
lines [21] [12], there are no reports of the detection of 
T-UCRs in serum samples from cancer patients. We 
provided the first evidence that T-UCRs can be detected 
in serum samples from cancer patients, suggesting that 
T-UCRs are more likely to be promising serum markers. 
Although PSA has been mainly used as a serum marker 
for PC, one of the issues with PSA is its low specificity 
in PC patients and false-positive results in BPH 
patients [22]. In contrast, the expression of Uc.63+ was 
significantly upregulated in the serum from PC patients 
compared with that from BPH patients. Moreover, 
we revealed that the expression of Uc.63+ in serum 
was remarkably upregulated in CRPC patients, and 
evaluation of its expression level in PC patients could 
be a useful biomarker for predicting the sensitivity to 
docetaxel treatment and clinical outcome for patients 
that receive docetaxel treatment. To date, we have no 
clinical applications to predict the response to docetaxel 
chemotherapy in PC patients. The present results 
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suggested that monitoring the expression of Uc.63+ 
in serum could potentially improve several steps of 
PC treatment, including the screening of PC patients 
using serum samples, and contribute to selection of the 
best treatment for PC patients: so-called “tailor-made 
treatment”. However, one concern is that the robust 
expression of Uc.63+ was observed in the nucleus in 
PC tissues, which indicates to us that the mechanism 
behind the secretion of nuclear Uc.63+ into serum is 
unclear. A recent report showed that the localization of 
Uc.8 was changed from the nucleus to the cytoplasm 
according to the tumor grading [23]. It is our current 
important task to determine the fundamental machinery 
of Uc.63+ secretion, which could further support the 
utility of Uc.63+ as a serum biomarker in PC patients. 
What is more, although expression and function of AR 
is still relevant in CRPC, we used DU145 and PC3 
(AR negative cells) as CRPC model in this research. 
CRPC cell lines which express AR will be needed 
to verify the current data. In closing, we found that 
T-UCR Uc.63+ was overexpressed in PC and showed 
that Uc.63+ modulated the expression of MMP2 via the 
regulation of miR-130b. Additionally, Uc.63+ promoted 
docetaxel resistance by regulating the expression of AR. 
Furthermore, the expression of Uc.63+ in the serum 
was dramatically changed through the carcinogenesis 
and progression of PC from BPH to CRPC. Although 
additional studies will likely be needed to further 
advance our understanding of how Uc.63+ contributes 
to PC progression, the data presented here highlight 
the great potential of Uc.63+ as a serum biomarker and 
therapeutic target in patients with PC.
Figure 5: Uc.63+ increases MMP2 through regulation of miR-130b. (A) The complementary sites between Uc.63+ and miR-
130b. (B) The result of qRT-PCR for the expression of miR-130b in prostate cancer (PC) cell lines (LNCaP, DU145, and PC3). (C) The 
correlation between Uc.63+ and miR-130b in PC tissues. Spearman correlation coefficient and P-values are indicated. (D) The result of 
qRT-PCR for the expression of miR-130b in PC tissues and non-neoplastic prostate (N) tissues. (E) qRT-PCR analysis for the expression 
of miR-130b in LNCaP cells transfected with Uc.63+ expression vector or empty vector. The results are expressed as the mean and S.D. of 
triplicate measurements. ***P <0.001. (F) Western blot analysis of MMP2 and β-actin in LNCaP cells transfected with Uc.63+ expression 
vector or empty vector. β-actin was used as a loading control. (G) The result of qRT-PCR for the expression of miR-130b in LNCaP cells 
transfected with Uc.63+ (LNCaP Uc.63+#1) transfected with miR-130b mimics or negative control. The results are expressed as the mean 
and S.D. of triplicate measurements. ***P <0.001. (H) Western blot analysis of MMP2 and β-actin in LNCaP Uc.63+#1 cells transfected 
with miR-130b mimics or negative control. β-actin was used as a loading control. (I) Wound healing assay in LNCaP Uc.63+#1 cells 
transfected with miR-130b mimics or negative control. Wound closures were evaluated by wound contraction percentage and closure time 
at 0, 12, and 24 hours after scratching. The results are expressed as the mean and S.D. of triplicate measurements. **P <0.01.
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MATERIALS AND METHODS
Cell lines
Three PC cell lines (LNCaP, PC3, and DU145) were 
purchased from the American Type Culture Collection 
(Manassas, VA, USA). PC3 and DU145 cell lines were 
maintained in RPMI 1640 (Nissui Pharmaceutical 
Co. Ltd., Tokyo, Japan) containing 10% fetal bovine 
serum (FBS, BioWhittaker, Walkersville, MD, USA), 
2 mM L-glutamine, 50 U/mL penicillin, and 50 g/mL 
streptomycin in a humidified atmosphere of 5% CO2 
and 95% air at 37°C. LNCaP cells were withdrawn from 
hormone effects in the medium by culture with medium 
containing charcoal/dextran stripped FBS for 2 days 
before treatment. DHT (10 nM) or vehicle control (0.5% 
ethanol) was added to the cells. Some experiments were 
examined 24 h later.
Tissue samples
For qRT-PCR, 20 PC tissue samples and 8 
non-neoplastic prostate tissue samples were used 
(Supplementary Table 1). The non-neoplastic prostate 
tissue samples were obtained at biopsy or autopsy, 
as described as previously [24]. The samples were 
immediately frozen in liquid nitrogen and stored at -80°C 
until use. For ddPCR, 5-mL serum samples collected from 
79 patients, including 10 with BPH, 24 with localized PC, 
18 with hormone-dependent PC, and 27 with CRPC, were 
used (Supplementary Table 2). The Institutional Review 
Board of Hiroshima University Hospital approved this 
study (approval no.E-688), and appropriate informed 
consent was obtained from each patient. The samples were 
collected from patients at Hiroshima University Hospital 
or an affiliated hospital. This study was conducted 
in accordance with the Ethical Guidance for Human 
Genome/Gene Research of the Japanese Government.
Quantitative RT-PCR analysis
Total RNA was isolated from frozen samples or 
cancer cell lines using Isogen (Nippon Gene, Tokyo, 
Japan), and 1 g of total RNA was converted to cDNA 
with a First Strand cDNA Synthesis Kit (Amersham 
Biosciences Corp., Piscataway, NJ, USA). The qPCR 
was performed with a SYBR Select Master Mix (Applied 
Biosystems, Austin, TX, USA). The primer sequences 
for the detection of each T-UCR, AR, PSA, or XPO1 are 
described in Supplementary Table 3. Real-time detection 
of the emission intensity of SYBR green bound to double-
stranded DNA was performed with a CFX Connect 
Real-Time System (Bio-Rad Laboratories, Hercules, 
CA, USA). ACTB-specific PCR products, which were 
amplified from the same RNA samples, served as internal 
controls. To quantify the level of miRNAs, TaqMan 
assays were performed as described previously [25] The 
expression values were normalized to the expression of 
the small RNA gene RNU6, and the relative quantification 
was determined using the ΔΔCt method as described 
previously [26].
Droplet digital PCR
Primers and TaqMan probes are described in 
Supplementary Table 4. ddPCR samples for Uc.63+ 
were prepared with a 20-μL reaction mixture containing 
10 μL ddPCR Supermix for Probes (no dUTP, Bio-Rad), 
500 nM of each forward primer and reverse primer, and 
250 nM probe (FAM), and synthesized cDNA droplets 
were generated with 70 μL of oil using a QX100 droplet 
generator (Bio-Rad). Amplification was performed at 
95°C for 10 min, followed by 40 cycles at 94°C for 30 
s and 40 cycles at 57°C for 1 min using a C1000 Touch 
thermocycler (Bio-Rad). After amplification, the droplets 
were read on a QX100 droplet reader (Bio-Rad) and 
analyzed with QuantaSoft software V1.7.4 (Bio-Rad). 
The QuantaSoft software measured the number of positive 
versus negative droplets. Their ratio was then fitted to a 
Poisson distribution to determine the copy number of the 
target molecule as copies/μL.
In situ hybridization
Sections 10-μm thick were rehydrated as described 
above. Thereafter, sections were treated with 0.2 M 
sodium chloride and proteinase K. Slides were post-fixed, 
and sections were then demethylated with acetic anhydride 
and prehybridized. Hybridization was carried out in a 
humid chamber with 500 ng/mL of freshly prepared 
digoxigenin-labelled RNA probe of UC63. Sections were 
incubated for at least 48 hours at 65°C. The slides were 
washed and incubation of the secondary anti-digoxigenin 
antibody (Roche Diagnostics, Indianapolis, IN, USA) 
was carried out at 4°C overnight. The next day, sections 
were washed and developed using Nitro Blue Tetrazolium 
Chloride/5-Brom-4-Chlor-3-Indolyl-Phosphat (Roche 
Diagnostics, Indianapolis, IN, USA).
RNA interference (RNAi) and expression vector
Silencer® Select (Ambion, Austin, TX) against 
Uc.63+ was used for RNA interference. Two independent 
oligonucleotides and negative control siRNA (Invitrogen, 
Carlsbad, CA, USA) were used. The sequence of siRNA#1 
was 5’-AAAGAUGUUAACACUACCUga-3’, and that of 
siRNA#2 was 5’-UUUGGUGCUAAAUUUAUGCac-3’. 
A total of 1.0 x 106 cells of PC3 or DU145 were plated 
on a 10-cm culture dish 24 h before transfection. 
Transfection was performed using Lipofectamine 
RNAiMAX (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer’s instructions. Cells were used 48 h 
after transfection in each of the experiments and assays. 
For constitutive expression of Uc.63+, cDNA was PCR 
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amplified and subcloned into pcDNA 3.1 (Invitrogen, 
Carlsbad, CA, USA). The pcDNA-Uc.63+ expression 
vector was transfected into LNCaP cells with FuGENE6 
(Roche Diagnostics), according to the manufacturer’s 
instructions.
Cell growth assay and wound healing assay
To examine cell growth, an MTT assay was 
performed as described previously [27]. Cell growth was 
monitored after 1, 2, and 4 days. Cells were seeded onto 
fibronectin-coated 6-well plates in 2 mL medium and 
incubated at 37°C for 12 h. A clear area was scraped with 
a plastic tip. Migration of cells into wounded areas was 
evaluated with an inverted microscope [28].
Western blot analysis
Cells were lysed in SDS buffer. Concentrations 
were determined by Bradford protein assay (Bio-Rad, 
Richmond, CA, USA) with BSA used as the standard. The 
lysates (40 μg) were solubilized in Laemmli sample buffer 
by boiling and then separated by 10% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis followed 
by electro-transfer onto a nitrocellulose filter. The filter 
was incubated for 1 h at room temperature with primary 
antibody. AR antibody (Thermo Fisher Scientific, MA, 
USA) and MMP2 antibody (Kyowa Pharma Chemical, 
Toyama, Japan) were used. Peroxidase-conjugated anti-
mouse or anti-rabbit IgG was used in the secondary 
reaction. Immunocomplexes were visualized with an 
ECL Plus Western Blot Detection System (Amersham 
Biosciences, Piscataway, NJ, USA). β-Actin (Sigma-
Aldrich, MO, USA) was detected as a loading control.
Secreted PSA protein level in cell culture 
supernatants
Secreted PSA protein levels in cell culture 
supernatants were determined by LUMIPULSE 
Presto PSA (Fujirebio Inc., Tokyo, Japan) according 
to the manufacturer’s instructions. Serial dilutions of 
recombinant human PSA were used to plot the standard 
curve.
Drug treatment
Docetaxel was obtained from Sanofi-Aventis 
and handled according to the manufacturer’s 
recommendations. Cell lines treated with vehicle (0.5% 
ethanol) or escalating doses of docetaxel were assessed 
for cell viability. MTT assay was performed at 48 hours 
after docetaxel chemotherapy [29]. Drug sensitivity curves 
and IC
50
 values were calculated using GraphPad Prism 4.0 
software (GraphPad Software Inc., San Diego, CA, USA). 
The main assessment of the end-point of chemotherapy 
was PSA response according to the criteria of the Prostate 
Cancer Clinical Trials Working Group (PCWG3) [30]. 
The PCWG3 defines progressive disease as an increase 
of ≥25% (at least 2 ng/mL) over the baseline value after 
12 weeks of chemotherapy, with confirmation by a second 
PSA value at least 3 weeks later. Treatment outcome of 
these 27 patients are summarized in Supplementary Table 
5.
Transfection of miR-130b mimics
miR-130b mimics (target sequence 
ACUCUUUCCCUGUUGCACUAC, Thermo Fisher 
Scientific, MA, USA) was used for transfection of miR-
130b. Transfection was performed with Lipofectamine 
RNAiMAX (Invitrogen, Carlsbad, CA, USA). Following 
the manufacture’s protocol.
Statistical analysis
All experiments were repeated at least three times 
with each sample in triplicate. The results are expressed 
as the mean ± S.D. of triplicate measurements. Sample 
sizes for relevant experiments were determined by 
power analysis. Statistical differences were evaluated 
using the two-tailed Student t-test or Mann-Whitney U-
test. Statistical analyses were conducted primarily using 
GraphPad Prism software (GraphPad Software Inc.).
Abbreviations
4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium 
bromide: MTT, Androgen receptor: AR, Benign prostatic 
hyperplasia: BPH, Castration-resistant prostate cancer: 
CRPC, Dihydrotestosterone: DHT, Droplet digital PCR: 
ddPCR, Hormone-dependent PC: HDPC, Noncoding 
RNAs: ncRNAs, Matrix metallopeptidase 2: MMP2, 
Metastatic PC: meta PC, Prostate cancer: PC, Prostate 
Cancer Clinical Trials Working Group: PCWG3, Prostate-
specific antigen: PSA, Ratio of tumor/non-neoplastic 
prostate: T/N ratio, Transcribed ultraconserved regions : 
T-UCRs.
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